Follows people newly diagnosed with axial spondyloarthritis in the UK

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults and teenagers aged 16 and over who were newly diagnosed with axial spondyloarthritis in the last 6 months and have not yet taken biologic therapy.

Age

From 16 years up to 50 years.

Sex

All sexes can join.

Disease stage

A doctor diagnosed axial spondyloarthritis (including ankylosing spondylitis) within the last 6 months before the start of the study.

Earlier treatment

No biologic therapy before (the study enrols people who have not had biologic therapy).

Main reasons for not taking part

• Younger than 16 years
• Cannot communicate in English
• Cannot give informed consent

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 16 and 50 years old?YesNo

What the trial wants to find out

The British Axial Spondyloarthritis Cohort (BAxSIC) study has been established under the auspices of the British Society for Spondyloarthritis (BRITSpA) in collaboration with the National Axial Spondyloarthritis Society (NASS) to provide real-world data to evaluate the impact of delay in diagnosis (from symptom onset to diagnosis) on work participation and functional outcomes and the natural history and impact of newly-diagnosed axial Spondyloarthritis, including disease activity, pain, fatigue, functional and work outcomes, comorbidities, therapies in the United Kingdom (UK). The study is a prospective cohort, enrolling patients attending rheumatology clinics in the UK who are newly diagnosed with axial Spondyloarthritis and naïve to biologic therapy.

Treatments tested

• No intervenetion